Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday? - Mersana Therapeutics (NASDAQ:MRSN)

Wedbush Reaffirms Outperform Rating for Mersana Therapeutics (NASDAQ:MRSN)

Wedbush restated an "outperform" rating and set a $4.00 target price (down previously from $7.00) on shares of Mersana Therapeutics in a research report on Friday.

Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday? - Mersana Therapeutics (NASDAQ:MRSN)

On Friday, Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin. Emi-Le was generally well tolerated, with no Grade 4 or 5 treatment-related adverse events reported. At intermediate doses in the trial (38.1 mg/m2 to 67.4 mg/m2), the confirmed objective response rate among evaluable patients was 23% (6 of 26 patients) across all B7-H4 high tumors and 23% (3 of …

Mersana Therapeutics Announces Positive Initial Clinical Data and FDA Fast Track Designation for Emiltatug Ledadotin (XMT-1660)

Mersana Therapeutics, Inc. recently disclosed encouraging updates in a Form 8-K report filed with the Securities and Exchange Commission. The company unveiled positive initial clinical data from the Phase 1 clinical trial of Emiltatug Ledadotin (XMT-1660) and the newly granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the Emi-Le treatment. […]

FDA grants additional FTD to Mersana’s XMT-1660 for breast cancer - BioTuesdays

Mersana Therapeutics (NASDAQ:MRSN) has announced that the FDA has granted an additional fast track designation (FTD) to its emiltatug ledadotin (XMT-1660) for the treatment of advanced or metastatic breast cancer. The company also announced that the World Health Organization (WHO) has approved emiltatug ledadotin (abbreviated as Emi-Le) as XMT-1660’s international non-proprietary name (INN). The FDA previously granted FTD to Emi-Le for the treat…

FDA Grants Fast Track Status to Mersana's Breast Cancer Drug Emi-Le for Expanded Use

Mersana's emiltatug ledadotin receives additional FDA Fast Track designation for treating HER2 low/negative breast cancer, expanding its potential therapeutic reach.